Skip Navigation



Annals of Oncology Advance Access published online on April 13, 2005
Annals of Oncology, doi:10.1093/annonc/mdi192
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/6/847    most recent
mdi192v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mosolits, S.
Right arrow Articles by Mellstedt, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mosolits, S.
Right arrow Articles by Mellstedt, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received January 31, 2005
Accepted February 1, 2005

Review

Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results

S. Mosolits 1, G. Ullenhag 2, and H. Mellstedt 1*

1 Immune and Gene Therapy Laboratory, Department of Oncology, Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden
2 Department of Oncology, Uppsala University Hospital, Uppsala, Sweden

* To whom correspondence should be addressed.
H. Mellstedt, E-mail: hakan.mellstedt{at}karolinska.se


  Abstract

Gastrointestinal (GI) malignancies are the most common types of human cancers. Despite the introduction of new cytotoxic drugs, a large proportion remains incurable. There is a great need to develop new complementary therapeutic modalities. Strategies exploiting targeted therapies are expanding. The focus of the present article is to review active specific immunotherapy (vaccination) in patients with GI malignancies. The review comprises a description of the immunogenicity of GI malignancies, various types of tumour antigens and mechanisms of action of cancer vaccines. Tumour escape from immune surveillance, vaccine strategies and adjuvants are also described. Clinical and immunological endpoints of cancer immunotherapy are outlined. Results of therapeutic vaccine trials published mainly during the last 5 years in PubMed enrolling a minimum of six patients with GI malignancies are included. Studies presented at the two last annual meetings of the American Society of Clinical Oncology are also covered. More than 2000 patients have been vaccinated with tumour antigens (self antigens). The procedure is safe and no autoimmune disorders have been observed after >4 years follow-up in a substantial number of patients. Humoral and cellular tumour antigen-specific immune responses were induced. A correlation between immune responses and prolonged overall survival was seen in several studies. The most encouraging results were noted in randomised controlled phase II/III trials including over 1300 colorectal carcinoma patients with minimal residual disease. A statistically significantly improved disease-free or overall survival was shown either in all vaccinated or in sub-groups of patients. Promising results were also reported in pancreatic and hepatocellular carcinoma. If the results of the randomised controlled trials hold true, active specific immunotherapy may provide a new promising targeted therapeutic approach in GI malignancies with minimal toxicity. Further enlarged randomised controlled studies are warranted to confirm the results, particularly in colon carcinoma with minimal residual disease.

Keywords: clinical effects; gastrointestinal tumours; immune response; therapy; vaccination.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
P. Correale, P. Tagliaferri, A. Fioravanti, M. T. Del Vecchio, C. Remondo, F. Montagnani, M. S. Rotundo, C. Ginanneschi, I. Martellucci, E. Francini, et al.
Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial)
Clin. Cancer Res., July 1, 2008; 14(13): 4192 - 4199.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
C Bauer, F Bauernfeind, A Sterzik, M Orban, M Schnurr, H A Lehr, S Endres, A Eigler, and M Dauer
Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model
Gut, September 1, 2007; 56(9): 1275 - 1282.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
W. J. Lesterhuis, I. J. M. de Vries, D. H. Schuurhuis, A. C. I. Boullart, J. F. M. Jacobs, A. J. de Boer, N. M. Scharenborg, H. M. H. Brouwer, M. W. M. M. van de Rakt, C. G. Figdor, et al.
Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests
Ann. Onc., June 1, 2006; 17(6): 974 - 980.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Nagorsen and E. Thiel
Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer.
Clin. Cancer Res., May 15, 2006; 12(10): 3064 - 3069.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.